Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The PAAT Act requires Medicare Part D prescription drug plans to cover all FDA-approved drugs used to treat autoimmune diseases, hemophilia, and Von Willebrand disease, starting in 2027. The bill also limits how often insurance companies can require "prior authorization"—a pre-approval process—for these medications to once per year, with narrow exceptions for drugs typically used for 12 months or less, controlled substances, or drugs with special safety monitoring requirements. This legislation affects Medicare beneficiaries with autoimmune and blood disorders, as well as the private insurance companies and Medicare Advantage plans that administer prescription drug coverage. The bill contains no specific federal funding provisions, as it primarily mandates coverage requirements rather than new spending. The requirements take effect January 1, 2027, giving plans time to adjust their formularies and prior authorization procedures.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.